Viagra vs Vardenafil (Levitra/Staxyn): Head-to-Head Efficacy Comparison

How PDE5 Inhibitors Work for Erectile Dysfunction

Sildenafil and vardenafil belong to the same pharmacological class. Both block phosphodiesterase type 5, the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in penile smooth muscle. When cGMP accumulates, arterial blood flow to the corpora cavernosa increases and an erection can occur in the presence of sexual stimulation.

The difference between these two drugs is not in their mechanism but in their molecular selectivity and pharmacokinetic profiles. Vardenafil has roughly 10-fold higher in-vitro potency for PDE5 than sildenafil 1. That laboratory finding, though, does not translate into a 10-fold clinical advantage because dosing is adjusted to match potency. Sildenafil 100 mg and vardenafil 20 mg produce similar peak plasma drug concentrations relative to their IC50 values. The 2005 American Urological Association (AUA) guideline on ED management stated that "available evidence does not allow us to distinguish between PDE5 inhibitors based on efficacy" 2.

Both drugs require sexual arousal to work. Neither creates spontaneous erections. This is a pharmacological feature, not a limitation, because PDE5 inhibition only amplifies the nitric oxide signaling pathway already activated by sexual stimulation 3.

Sildenafil Efficacy: What the Landmark Trial Showed

The Goldstein et al. 1998 study in the New England Journal of Medicine established PDE5 inhibition as a viable treatment for ED and led to sildenafil's FDA approval. This was a dose-response trial of 532 men with organic, psychogenic, or mixed ED randomized to sildenafil 25, 50, or 100 mg or placebo taken as needed over 24 weeks 3.

Results were measured using the International Index of Erectile Function (IIEF). Men receiving sildenafil 100 mg scored a mean erectile function domain score of 25.2 versus 15.0 for placebo. That is a 10-point absolute improvement over baseline and roughly a 6-to-8-point advantage over placebo, depending on the population subset. Successful intercourse attempts (measured by the Sexual Encounter Profile question 3) occurred in 69% of sildenafil attempts versus 22% for placebo 3.

A later meta-analysis of 27 randomized controlled trials covering 6,659 sildenafil-treated men confirmed a weighted mean IIEF erectile function domain improvement of +8.2 points above placebo (95% CI 7.4 to 9.0) 4. Efficacy held across diabetes, spinal cord injury, post-prostatectomy, and psychogenic ED subgroups, although response rates were lower in post-radical-prostatectomy patients (approximately 43% vs. 15% placebo).

Vardenafil Efficacy: The Diabetes and General ED Trials

Vardenafil's key data came from several phase III trials, including the Porst et al. 2003 study published in the International Journal of Impotence Research. That trial enrolled 580 men with type 1 or type 2 diabetes and ED, randomizing them to vardenafil 10 mg, 20 mg, or placebo over 12 weeks 5.

Diabetic ED is notoriously harder to treat because of endothelial damage, neuropathy, and impaired nitric oxide synthesis. The results were still positive. Vardenafil 20 mg improved the IIEF erectile function domain score by a mean of 6.6 points above baseline (compared to +1.4 for placebo). The proportion of successful intercourse attempts was 49% for vardenafil 20 mg versus 23% for placebo 5.

In non-diabetic general ED populations, vardenafil performed comparably to sildenafil. A large phase III trial by Hellstrom et al. (N=805) found that vardenafil 20 mg produced IIEF erectile function scores of 25.9 versus 15.6 for placebo after 12 weeks 6. Those numbers closely mirror sildenafil's results from the Goldstein trial. The Hellstrom data also showed that 80% of intercourse attempts were successful with vardenafil 20 mg, a figure within the range seen across sildenafil trials.

Direct Comparisons: What the Head-to-Head Data Shows

No single, large, regulatory-grade head-to-head trial has compared sildenafil and vardenafil as primary endpoints. This is the uncomfortable truth in PDE5 inhibitor comparisons. Most "comparison" claims come from indirect cross-trial analysis or small investigator-initiated studies.

A 2006 crossover study by Rubio-Aurioles et al. (N=1,057) compared sildenafil and vardenafil in a preference-based design rather than a strict superiority design 7. Patients used each drug for 4 weeks in randomized order, then chose a preference. The erectile function domain scores were nearly identical: 25.6 for sildenafil versus 25.4 for vardenafil. Patient preference split close to evenly, with 49.3% preferring sildenafil and 50.7% preferring vardenafil. The difference was not statistically significant.

A 2011 systematic review and network meta-analysis published in the European Urology journal pooled data from 82 randomized controlled trials across all four major PDE5 inhibitors 8. The odds ratios for successful intercourse versus placebo were: sildenafil 3.97 (95% CI 3.25 to 4.85), vardenafil 4.25 (95% CI 3.28 to 5.51), and tadalafil 4.66 (95% CI 3.71 to 5.86). The confidence intervals overlap substantially, confirming comparable efficacy across the class.

Dr. Arthur Burnett, professor of urology at Johns Hopkins Medicine, summarized the state of evidence in a 2006 review: "The choice among PDE5 inhibitors should be individualized based on the patient's preferences, the pharmacokinetic profile, and the side effect profile, rather than presumed differences in efficacy" 9.

HealthRX Comparison Framework: Sildenafil vs Vardenafil

| Parameter | Sildenafil (Viagra) | Vardenafil (Levitra/Staxyn) | |---|---|---| | Typical starting dose | 50 mg | 10 mg | | Maximum dose | 100 mg | 20 mg (tablet) or 10 mg (ODT) | | Time to peak plasma | 60 min (median) | 40 to 60 min (tablet), 60 min (ODT) | | Earliest reported effect | 30 min | 25 min in some studies | | Effective duration | 4 to 5 hours | 4 to 5 hours | | High-fat meal effect | Delays Tmax by ~60 min, reduces Cmax ~29% | Delays Tmax moderately, Cmax reduced ~18% | | IIEF EF domain gain vs placebo | +6 to +8 points | +5 to +7 points | | Successful intercourse (top dose) | 63 to 82% | 65 to 80% |

Onset, Duration, and Pharmacokinetic Differences

Sildenafil reaches peak plasma concentration (Tmax) in approximately 60 minutes when taken on an empty stomach. A high-fat meal can push that to nearly 2 hours and lower Cmax by about 29% 10. This is why the prescribing label recommends taking sildenafil at least 30 to 60 minutes before anticipated intercourse, ideally without a heavy meal.

Vardenafil's Tmax is slightly faster in some pharmacokinetic studies, reaching peak levels in 40 to 60 minutes for the standard film-coated tablet 11. The orally disintegrating tablet (Staxyn) is a different formulation. Staxyn is not bioequivalent to the standard Levitra tablet. Its Tmax is approximately 60 minutes but it can be taken without water, which some men find more convenient and discreet 11.

A practical consideration: both drugs last approximately 4 to 5 hours in the effective window. Neither provides the extended 36-hour window of tadalafil. For men who want a longer window of responsiveness, tadalafil (Cialis) is a different conversation. But for a planned encounter within a defined window, sildenafil and vardenafil are functionally equivalent in duration.

The half-life of sildenafil is 3 to 5 hours. Vardenafil's half-life is 4 to 5 hours. These numbers are close enough that most men will not notice a meaningful difference in how long the medication remains active.

Side Effects and Tolerability

Both drugs share a common side-effect profile because they inhibit the same enzyme. The most frequent adverse events across trials are headache (10 to 16%), flushing (5 to 12%), nasal congestion (2 to 9%), and dyspepsia (3 to 7%) 3 5.

Sildenafil has a known cross-reactivity with PDE6, the phosphodiesterase found in retinal photoreceptors. This produces the "blue tint" visual disturbance (cyanopsia) reported by roughly 3% of men at the 100 mg dose 3. Vardenafil has less PDE6 affinity, and visual disturbances are reported in fewer than 1% of vardenafil users 12.

Vardenafil carries a specific cardiac caution. It can prolong the QTc interval by approximately 8 milliseconds at the 10 mg dose and up to 10 ms at supratherapeutic doses 12. The FDA label for vardenafil advises against use in men taking Class IA or Class III antiarrhythmic drugs (e.g., amiodarone, sotalol, procainamide). Sildenafil does not carry this specific QTc warning in its ED labeling, though all PDE5 inhibitors have mild vasodilatory effects.

Both drugs are absolutely contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate/dinitrate) due to the risk of severe, potentially fatal hypotension 13.

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, noted in a 2005 clinical review that "the tolerability profiles of available PDE5 inhibitors are sufficiently similar that most adverse events resolve with dose adjustment rather than a drug switch" 14.

Efficacy in Special Populations

Diabetes

Diabetic ED affects 35 to 75% of men with diabetes and responds less robustly to PDE5 inhibitors than ED in the general population. In the Porst et al. trial, vardenafil 20 mg achieved 49% successful intercourse in diabetic men 5. For sildenafil, a pooled analysis of 11 trials found a 63% success rate in diabetic men on sildenafil versus 33% on placebo 15. These figures are not directly comparable due to differences in trial design, inclusion criteria, and diabetes severity, but both drugs show clinically meaningful benefit in this difficult population.

Post-Prostatectomy

Nerve-sparing radical prostatectomy damages the cavernous nerves and reduces natural erectile signaling. Response rates to PDE5 inhibitors drop significantly. Sildenafil trials in post-prostatectomy patients report success rates of 35 to 43% at the 100 mg dose versus 15% for placebo, depending on the degree of nerve sparing 16. Vardenafil trials show comparable but similarly reduced response in this population, with 37% successful intercourse in bilateral nerve-sparing patients 17.

Older Adults

Both drugs work in men over 65, but dose adjustments are common. Sildenafil 25 mg is the recommended starting dose in men over 65 because of reduced hepatic clearance. Vardenafil 5 mg serves the same role. Efficacy in older men is preserved, though comorbidities (cardiovascular disease, diabetes, polypharmacy) may reduce overall response.

Cost and Access Considerations

Sildenafil went generic in the United States in December 2017 after Pfizer's patent expired. Generic sildenafil tablets are now available for $1 to $3 per dose at most pharmacies, making it the most affordable PDE5 inhibitor by a wide margin.

Vardenafil (Levitra) became available as a generic in 2018. Generic vardenafil tablets typically cost $3 to $8 per dose, still more affordable than brand Levitra but roughly 2 to 4 times the price of generic sildenafil 18. Staxyn (vardenafil ODT) remains brand-only in many markets and costs significantly more.

For men whose insurance does not cover ED medications (many plans exclude them), the out-of-pocket price difference may steer the decision. If cost is a primary factor and both drugs are equally effective for a given patient, generic sildenafil is the rational first choice.

How to Choose Between Sildenafil and Vardenafil

The clinical decision between these two drugs rarely depends on efficacy data alone. A practical approach:

Try sildenafil first if cost matters, if you have no contraindications, and if you have not tried a PDE5 inhibitor before. Its decades-long safety record, broad generic availability, and well-understood dosing make it the default first-line option in most guidelines 2.

Consider vardenafil if sildenafil causes bothersome visual disturbances (the blue-tint phenomenon), if you want the ODT formulation for convenience, or if sildenafil at maximum dose was partially effective and you want to trial a different molecular option. Some men who respond poorly to one PDE5 inhibitor respond to another, though the mechanism for this is not fully understood 7.

Avoid vardenafil specifically if you take Class IA or Class III antiarrhythmics or have congenital long QT syndrome. Sildenafil does not carry the same QTc prolongation concern at standard doses.

Both drugs should be trialed at least 4 to 6 times before declaring failure. Early attempts may not reflect true drug response because of performance anxiety, incorrect timing relative to food, or suboptimal dosing. The AUA guideline recommends a minimum of 6 to 8 attempts before switching agents 2.

Switching Between PDE5 Inhibitors

Men who do not respond to one PDE5 inhibitor have a 30 to 50% chance of responding to a different one. A 2004 study by McMahon (N=904) found that 42% of sildenafil non-responders achieved successful intercourse after switching to another PDE5 inhibitor 19. The switch does not require a washout period. Both sildenafil and vardenafil clear the body within 24 hours, so a man can start the new drug at his next planned encounter.

Physicians at HealthRX typically recommend confirming that non-response is genuine (correct dose, empty stomach, adequate sexual stimulation, at least 6 attempts) before switching. Dose escalation within the same drug is the first step. Switching is the second.

The 2018 AUA/SMSNA guideline update affirmed: "Clinicians should inform patients who fail to respond to one PDE5 inhibitor that a trial of a different PDE5 inhibitor may be successful" 20.